XNASDAWN
Market cap1.19bUSD
Jan 10, Last price
11.80USD
1D
-3.28%
1Q
-14.99%
IPO
-50.19%
Name
Dot Therapeutics-2 Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-189m
L+42.93%
CFO
-147m
L+33.66%
Profile
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 206,447 | 147,440 | |||
Unusual Expense (Income) | |||||
NOPBT | (206,447) | (147,440) | |||
NOPBT Margin | |||||
Operating Taxes | (10,005) | ||||
Tax Rate | |||||
NOPAT | (206,447) | (137,435) | |||
Net income | (188,917) 42.93% | (132,176) 87.64% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 161,409 | 166,543 | |||
BB yield | -13.86% | -11.82% | |||
| Debt | |||||
Debt current | 816 | 405 | |||
Long-term debt | 408 | 1,221 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (365,123) | (340,643) | |||
| Cash flow | |||||
Cash from operating activities | (146,853) | (109,874) | |||
CAPEX | (224) | (26) | |||
Cash from investing activities | 128,378 | (255,074) | |||
Cash from financing activities | 163,997 | 165,901 | |||
FCF | (206,288) | (137,870) | |||
| Balance | |||||
Cash | 366,347 | 342,269 | |||
Long term investments | |||||
Excess cash | 366,347 | 342,269 | |||
Stockholders' equity | (458,567) | (269,732) | |||
Invested Capital | 805,923 | 877 | |||
ROIC | 95.20% | ||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 79,773 | 65,467 | |||
Price | 14.60 -32.16% | 21.52 27.72% | |||
Market cap | 1,164,686 -17.33% | 1,408,845 34.96% | |||
EV | 799,563 | 1,068,202 | |||
EBITDA | (206,064) | (146,909) | |||
EV/EBITDA | |||||
Interest | 4,746 | ||||
Interest/NOPBT | |||||